Αρχική World News Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in... World News Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer Από Ogkologos - 3 Νοεμβρίου, 2025 470 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ELCC 2015 News: ‘Real-World’ EGFR Mutation Frequency Results From a Large... 16 Απριλίου, 2015 Activity of Targeted/Immune Therapy Approach in Patients with Advanced Urothelial Cancer 11 Μαΐου, 2021 2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’ 17 Ιανουαρίου, 2022 An Intensive Follow-Up in Surgically Treated Patients for Endometrial Cancer Does... 29 Ιουλίου, 2022 Φόρτωση περισσοτέρων HOT NEWS New study to detect oesophageal cancer earlier Doctors Seem To Be Biased Against Unmarried Cancer Patients, Offer Them... FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple... Immunotherapy approved for some people with advanced melanoma in England